Michael Weber has been appointed to Ablative Solutions’ Scientific Advisory Board. Weber is an expert in the areas of hypertension and preventive cardiology, and is currently a professor of medicine at SUNY Downstate College of Medicine in, New York City, USA. He is also the editor-in-chief of The Journal of Clinical Hypertension. Weber was one of the founders of The American Society of Hypertension and has previously served as its president.
Ablative Solutions has developed a patented device, the Peregrine System, which is a percutaneous catheter designed to deliver diagnostic and therapeutic agents through vessel walls to the outer region of arteries. The Peregrine System has been cleared by the US Food and Drug Administration (FDA) for the infusion of diagnostic and therapeutic agents into the perivascular area.
Ablative Solutions is currently investigating the use of the Peregrine System in a clinical study in Europe intended to secure a CE mark. The System is being evaluated for renal denervation, providing a treatment that delivers therapy directly to the nerves that run along the perimeter of the renal artery. The interruption of these nerve pathways may have therapeutic implications for hypertension, metabolic syndrome, congestive heart failure and obesity. The system is not currently cleared or approved in the USA for renal denervation, or for the treatment of hypertension, metabolic syndrome, congestive heart failure or obesity.
“I am pleased to be joining the advisors to Ablative Solutions, which has conducted in-depth research on chemical neurolysis. Hypertension is a serious public health issue. The approach being pursued by the company toward sympathetic nerve modulation may provide a valuable addition to therapies for this condition,” observed Weber.